An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of DCLL9718S in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Patients With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 19
- 试验地点
- 8
- 主要终点
- Percentage of participants With Adverse Events (AEs)
研究概览
简要总结
This Phase Ia/Ib, open-label, multicenter study will evaluate the safety, tolerability, and preliminary efficacy of DCLL9718S as a single agent (Phase Ia, Arm A) in participants with relapsed or refractory AML or in combination with azacitidine (Phase Ib, Arm B) in participants with previously untreated AML who are not eligible for intensive induction chemotherapy. Each arm will consist of two stages: a dose-escalation stage and an expansion stage. The dose-escalation stage is designed to establish the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) for DCLL9718S alone (Arm A) or in combination with azacitidine (Arm B). The dose-expansion stage is designed to characterize the long-term safety and tolerability of DCLL9718S.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of AML per World Health Organization (WHO) criteria (except acute promyelocytic leukemia)
- •Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2
- •Adequate end-organ function
- •Willing and able to undergo a pre-treatment bone marrow aspirate and biopsy and subsequent bone marrow aspirates and biopsies during treatment
- •Specifically for participants in Arm A:
- •Age greater than or equal to (>/=) 18 years
- •Relapsed or refractory acute myeloid leukemia
- •Participants cannot have received more than two prior regimens
- •Specifically for participants in Arm B:
- •Treatment-naive participants with AML who are >/=75 years old
- •Treatment-naive participants unfit for induction chemotherapy for AML due to comorbidities who are >/=65 years old
排除标准
- •Diagnosis of acute promyelocytc leukemia
- •Prior allogeneic stem cell transplant or solid organ transplant
- •Active central nervous system (CNS) involvement by leukemia
- •History of idiopathic pulmonary fibrosis, organizing pneumonitis (for example [e.g.], bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis
- •Treatment with investigational therapy within 14 days prior to Cycle 1, Day 1
- •Treatment with a monoclonal antibody within 30 days prior to Cycle 1, Day 1
- •Positive for hepatitis C virus (HCV) antibody at screening
- •Active hepatitis B virus (HBV) infection
- •Known positivity for human immunodeficiency virus (HIV)
- •History of other malignancy within 2 years prior to screening
- •Family history of long QT syndrome, with a QTc interval greater than (>) 480 millisecond (msec) at screening, or taking concurrent medications known to prolong QT/QTc interval
研究组 & 干预措施
Arm A: DCLL9718S
Participants will receive escalating doses of DCLL9718S intravenously (IV) in each 21-day cycle to determine MTD and RP2D in dose-escalation stage followed by DCLL9718S IV at RP2D in each 21-day cycle in dose-expansion stage until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
干预措施: DCLL9718S (Drug)
Arm B: DCLL9718S and Azacitidine
Participants will receive escalating doses of DCLL9718S (starting dose: at least one dose level below a completed and tolerated DCLL9718S monotherapy in Arm A) IV in each 28-day cycle and azacitidine 75 milligrams per square meter (mg/m^2) subcutaneously (SC) or IV on Days 1-7 of each 28-day cycle to determine MTD and RP2D of DCLL9718S in dose-escalation stage followed by DCLL9718S IV at RP2D in each 28-day cycle and azacitidine 75 mg/m^2 SC or IV on Days 1-7 of each 28-day cycle in dose-expansion stage until disease progression, unacceptable toxicity, or any other discontinuation criteria are met. Azacitidine may also be given on Days 1-5 and Days 8-9 depending on institutional preference.
干预措施: DCLL9718S (Drug)
Arm B: DCLL9718S and Azacitidine
Participants will receive escalating doses of DCLL9718S (starting dose: at least one dose level below a completed and tolerated DCLL9718S monotherapy in Arm A) IV in each 28-day cycle and azacitidine 75 milligrams per square meter (mg/m^2) subcutaneously (SC) or IV on Days 1-7 of each 28-day cycle to determine MTD and RP2D of DCLL9718S in dose-escalation stage followed by DCLL9718S IV at RP2D in each 28-day cycle and azacitidine 75 mg/m^2 SC or IV on Days 1-7 of each 28-day cycle in dose-expansion stage until disease progression, unacceptable toxicity, or any other discontinuation criteria are met. Azacitidine may also be given on Days 1-5 and Days 8-9 depending on institutional preference.
干预措施: Azacitidine (Drug)
结局指标
主要结局
Percentage of participants With Adverse Events (AEs)
时间窗: Baseline up to end of study (up to approximately 3 years)
Percentage of Participants With Dose-Limiting Toxicities (DLTs)
时间窗: Cycle 1 Day 1 up to Cycle 2 Day 1 (Cycle length: 21 days for Arm A and 28 days for Arm B)
MTD of DCLL9718S
时间窗: Cycle 1 Day 1 up to Cycle 2 Day 1 (Cycle length: 21 days for Arm A and 28 days for Arm B)
RP2D of DCLL9718S
时间窗: Cycle 1 Day 1 up to Cycle 2 Day 1 (Cycle length: 21 days for Arm A and 28 days for Arm B)
次要结局
- Maximum Plasma Concentration Observed (Cmax) of DCLL9718S(up to 3 years)
- Total Clearance of DCLL9718S(up to 3 years)
- Terminal Half-Life (t1/2) of DCLL9718S(up to 3 years)
- Volume of Distribution Under Steady-State (Vss) of DCLL9718S(up to 3 years)
- Percentage of Participants With Complete Remission (CR), CR With Incomplete Blood Count Recovery (CRi), CR With Incomplete Platelet Count Recovery (CRp), and Overall Response, Assessed as per International Working Group (IWG) Criteria(From the date of first treatment to disease progression or relapse or death from any cause (up to approximately 3 years))
- Duration of Response, Assessed as per IWG Criteria(From the date of first response to the earliest recurrence or disease progression (up to approximately 3 years))
- Event-Free Survival (EFS), Assessed as per IWG Criteria(From the date of first treatment until treatment failure, relapsed from CR, CRp, or CRi, or death from any cause, whichever occurs first (up to approximately 3 years))
- Serum Concentration of DCLL9718S(up to 3 years)
- Plasma Concentration of Azacitidine(up to 3 years)
- Area Under the Concentration-Time Curve (AUC) of DCLL9718S(up to 3 years)
- Overall Survival(From the date of first treatment to the date of death from any cause (up to approximately 3 years))
- Progression-Free Survival (PFS), Assessed as per IWG Criteria(From the date of first treatment to disease progression or relapse or death from any cause (up to approximately 3 years))
- Change From Baseline in Anti-Drug Antibody (ADA) to DCLL9718S(Baseline up to end of study (up to approximately 3 years))